Merck & Co., Inc. Sees Unusually High Options Volume (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) saw unusually large options trading activity on Wednesday. Stock investors purchased 42,821 call options on the stock. This represents an increase of approximately 42% compared to the typical daily volume of 30,188 call options.

Merck & Co., Inc. Stock Up 1.1%

Shares of MRK stock opened at $127.61 on Thursday. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $131.74. The stock has a market cap of $315.16 billion, a P/E ratio of 35.95, a P/E/G ratio of 5.03 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a 50 day simple moving average of $120.93 and a two-hundred day simple moving average of $117.45.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. Finally, BMO Capital Markets increased their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $133.94.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $31,000. Finally, High Note Wealth LLC lifted its holdings in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.